Drug Profile

Research programme: cancer therapeutics - Exelixis

Alternative Names: XL541

Latest Information Update: 09 Mar 2011

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Exelixis
Class
Mechanism of Action Cyclin-dependent kinase 9 inhibitors; MTOR protein inhibitors; Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors; Sphingosine 1 phosphate receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
Available For Licensing Yes

22 Feb 2011 Research programme: cancer therapeutics - Exelixis is available for licensing as of 22 Feb 2011. http://www.exelixis.com/
22 Feb 2011 Discontinued - Preclinical for Cancer in USA (unspecified route)
18 Dec 2008 Preclinical trials in Cancer in USA (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com